← Back
Data updated: Jun 28, 2026
AIRGAS USA LLC
Pharma Pharmaceuticals
AIRGAS USA LLC is a pharmaceutical company with 5 FDA-approved products.
2013
Since
5
Drugs
-
Trials
8
New Drugs (2yr)
Modality:
5 Small Molecules
AIRGAS USA LLC's Key Drugs
AIRGAS USA LLC's core commercial portfolio centers on CARBON DIOXIDE, USP, HELIUM, USP, MEDICAL AIR, USP — its most strategically important drugs approved in the last 15 years.
AIRGAS USA LLC's Recent FDA Approvals
AIRGAS USA LLC secured 8 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
MEDICAL AIR, USP NDA
2026-02-17 CARBON DIOXIDE, USP NDA
2025-10-25 carbon dioxide
CARBON DIOXIDE, USP NDA
2025-06-16 carbon dioxide
CARBON DIOXIDE, USP NDA
2025-04-21 carbon dioxide
Carbon Dioxide, USP NDA
2025-02-02 carbon dioxide
Carbon Dioxide, USP NDA
2024-11-09 carbon dioxide, usp
CARBON DIOXIDE, USP NDA
2024-08-10 carbon dioxide
MEDICAL AIR, USP NDA
2024-07-13 medical air
AIRGAS USA LLC's Therapeutic Areas
Disease areas where AIRGAS USA LLC has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
AIRGAS USA LLC Pipeline Snapshot
Active clinical trials for AIRGAS USA LLC across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • CARBON DIOXIDE, USP leads revenue
- • 5 key drugs tracked
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Discontinued (0)
Company Info
- First Approval
- 2013-07-20
- Latest
- 2013-09-07
- Applications
- 5